- The Ohio medical cannabis program has seen growth accelerate.
- Health Canada added 3 licenses, leaving the total now at 677.
- 420 Investor model portfolios have gained 58.6-88.5% year-to-date, while the Global Cannabis Stock Index has gained 34.2%.
Representative Nadler introduced the MORE Act of 2021. Florida's Supreme Court upheld a lower court ruling from 2020 that will keep its vertical integration requirement in place. Ohio weekly medical cannabis sales now exceed $5 million.
Health Canada added 3 licenses, leaving the total at 677, including 2 that are expired, revoked or suspended.
During the week, I shared these posts with subscribers at 420 Investor:
Here are some of this week's highlights for Focus List names:
- ACB launched its Science & Innovation group focused on IP related to genetics and biosynthesis
- CRLBF Q1 revenue exceeded expectations, growing 10% sequentially to $179 million, with adjusted EBITDA at $35 million
- GNLN announced that its pending acquisition of KushCo cleared HSR review after the expiration of the waiting period.
- GRWG announced an acquisition in California that will add two stores
- HRVSF opened its 10th store in Pennsylvania
- KSHB announced that its pending acquisition by Greenlane cleared HSR review after the expiration of the waiting period.
- PLNHF Q1 revenue increased 42% to $23.8 million, with adjusted EBITDA of $5.2 million
- TCNNF announced the pending opening of its first retail cannabis store in Massachusetts on June 3rd
- TLLTF announced Airo Brands as a customer in Pennsylvania for filled vape products. The company reported Q1 revenue of $46.8 million and adjusted EBITDA of $6.2 million.
- UGRO authorized a $5 million share repurchase program
The Global Cannabis Stock Index rallied for the second straight week, ending the month down but well off the lows as it closed at 59.57, up 7.7%:
The index, which lost 34.1% in 2019 and lost 54.9% in 2018 after gaining 91.8% in 2017 and 88.8% in 2016, was up 5.2% in 2020. It has gained 34.2% in 2021 thus far. It currently includes 46 stocks and ended 2020 at 44.39:
420 Investor offers three model portfolios for subscribers, including two that are long-term focused and fully invested with a goal of beating the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week valued at $176,717, up 8.5%. The model portfolio, up 67.7% in 2021, gained 35.6% in 2020 and has increased 253.4% since April 2014. 420 Quality ended the week at $256,203, up 8.8% for the week, and is now up 58.6% in 2021 after gaining 42.8% in 2020. The model was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 412.4% since inception compared to the 26.3% decrease in the index. Flying High, which is focused on swing trades, ended the week valued at $475,864, up 10.2%. The model portfolio gained 52.7% in 2020 and is up 88.5% in 2021, and the return since inception in late 2013 has been 4659%.
After a strong rally to begin 2019, the cannabis sector experienced a sharp decline over the next year to unprecedented levels due to several negative developments, including the CannTrust fraud, the surprise termination of Bruce Linton as CEO of Canopy Growth, a disappointing roll-out of legalization in Canada, regulatory confusion in the U.S. regarding CBD and a slow roll-out of legalization in California, the vaping crisis and then financial turmoil and market disruptions due to the COVID-19 pandemic. The sector saw capital available to fund expansion dry up, a situation that continues to leave companies operating with negative cash flow severely challenged, as the availability is limited to stronger operators.
Cannabis stocks overreacted and put in a bottom in March 2020, and they are now benefiting from a perception that the industry offers strong growth prospects, something that wasn't clear then. A big change has been that the pandemic caused many regulators to permit previously prohibited types of retail activities, like curbside pickup and delivery. The legal market is rapidly capitalizing on becoming even more convenient than the illicit market, with the ability to order online. High unemployment and large deficits have begun to spur state legalization efforts as well as more favorable regulatory control at the local level. Access to capital has improved dramatically, and the leading companies are generating large and rapidly growing revenue and profits.
There are several potential catalysts ahead, including the FDA providing clarity on CBD regulation, progress in the Canadian legalization that commenced in October 2018 and that is beginning to include a broader set of products and the continued growth in German and Israeli MMJ and other international markets that have been slow to develop. The adult-use implementations in California and Massachusetts for adult-use were slow to roll out but are beginning to show great improvement. Michigan and Illinois legalized for adult-use at the end of 2019, and these markets are showing strong growth that could encourage other states to legalize. Voters in Arizona, Montana, South Dakota and New Jersey all approved adult-use legalization in November, and New Mexico, New York and Virginia have enacted legalization through the legislative process in 2021.
The big themes ahead are likely to be continued cross-industry investment into the sector and more consolidation in Canada and in the U.S., potential federal regulatory reform (SAFE Banking Act and other more comprehensive legislation, which could eliminate 280E taxation and enable trading on higher exchanges for MSOs as well as the broad usage of credit cards for cannabis purchases), steps to enable cannabis research, the roll out of MMJ in Germany, Mexico and in Australia as well as continued advances in South America and potential adult-use legalization in Israel and Mexico, new legal cannabis implementations in AZ, MT, NJ and SD, and MMJ implementations in AL, WV and VA, possible legalization via the legislatures in CT, DE, FL, MD, MN, NH, PA and RI and implementation of the NM, NY and VT commercial programs in 2022 and VA in 2024.
Here are some of the most interesting stories we published on New Cannabis Ventures this week:
- Stay on top of all of the NCV news on publicly-traded stocks
- Track cannabis stocks with the Global Cannabis Stock Index
- Follow Canadian Producers with the Canadian Cannabis LP Index
- Monitor the American Cannabis Operator Index
- Stay on top of the Ancillary Cannabis Index
- Access free Canadian cannabis investor resources
- Learn about our featured companies
- Check out our "Revenue Tracker"
- Discover upcoming new issues and IPOs
- Stay on top of upcoming earnings calls
- Subscribe to the free Weekly Newsletter
- Follow all the NCV news real-time, by liking the Facebook page
- Get the NCV App (Apple)
- Get the NCV App (Google Play)
- Find a job with a leading cannabis company
- Read my articles on the Forbes Contributor site
- Read my articles on Leafly
- Subscribe to the 420 Investor Monthly Newsletter ($199 year)
- Become a 420 Investor VIP Member ($599 year)
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
At New Cannabis Ventures, we work with several publicly-traded companies, including Ayr Strategies, Body and Mind, Charlotte's Web, Cresco Labs, Fire & Flower, Harborside, Jushi Holdings, KushCo Holdings, Lowell Farms, Plus Products, Rubicon Organics, TerrAscend, TPCO Holding Corp, urban-gro, Valens Company and Vireo Health, providing each of them with Investor Dashboards. Please see our disclaimer for more detail: http://www.newcannabisventures.com/disclaimer/
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.